Javier Rodriguez Joins Gilead Sciences’ Board of Directors
June 16 2020 - 4:05PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Javier
Rodriguez has been appointed to the company’s Board of Directors.
Mr. Rodriguez is the Chief Executive Officer of DaVita Inc., a
Fortune 500 company providing healthcare services to kidney disease
patients throughout the United States and internationally that
strives to improve patients’ quality of life through clinical
innovation and integrated, personalized care. From 2014 to 2019, he
was the CEO of DaVita Kidney Care, the company’s business unit that
treats patients with kidney failure and end-stage renal disease.
Mr. Rodriguez has spent more than 20 years in various executive
roles at DaVita, driving the company’s transformation for how
kidney care is delivered. In addition, he currently serves as a
member of the boards of directors of DaVita and the Denver Metro
Chamber of Commerce.
“We are very pleased to welcome Javier to Gilead's Board of
Directors,” said Daniel O’Day, Chairman and Chief Executive Officer
of Gilead Sciences. “He brings significant industry expertise and
the perspective of a visionary CEO. Javier is a valuable addition
to our Board as we continue to shape Gilead’s next chapter.”
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200616005328/en/
Douglas Maffei, PhD, Investors (650) 522-2739
Marni Kottle, Media (650) 522-5388
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024